… in psoriasis patients with low, stable disease activity. Although noninferiority regarding disease
activity was not demonstrated, DS of adalimumab, etanercept, … by a multicenter study [13]. …

… be a concern for patients and clinicians. Therefore, the aim of the current study was to evaluate
the … dose in patients who discontinued DR of adalimumab, etanercept or ustekinumab. …

… psoriasis, we recently conducted a randomized non-inferiority trial on DR of adalimumab,
etanercept and ustekinumab in patients … Down-titration and discontinuation strategies of tumour …

… Therefore, the aim of the current study was to evaluate the effectiveness of re-… Down-titration
of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. Acta …

… evidence, which predominantly consists of observational studies with no direct comparison
of tapered with non-tapered treatment, different patient selection (active disease at baseline) …

… with rheumatoid arthritis, psoriatic arthritis and ankylosing … confirms that adalimumab
down-titration in RA patients in remission, … A previous observational study suggested that …

… with rheumatoid arthritis, psoriatic arthritis and ankylosing … confirms that adalimumab
down-titration in RA patients in remission, … A previous observational study suggested that …

… and patient characteristics, we designed this observational study, … , dose reduction of
adalimumab or etanercept was non-inferior … showed that down-titration of biologics in RA patients …

… biologics, several observational studies showed that DR of adalimumab, … Down-titration
of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. Acta …

… tapering in psoriasis patients: four randomized controlled trials and 15 observational studies.
… and most thoroughly investigated for adalimumab, etanercept, and ustekinumab. Hereafter, …